VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Fluarix Influenza virus DNA vaccine M2-DNA/M2-Ad
Vaccine Information Vaccine Information
  • Product Name: Influenza Virus Vaccine
  • Tradename: Fluarix
  • Manufacturer: GlaxoSmithKline Biologicals
  • Vaccine Ontology ID: VO_0000045
  • CDC CVX code: 140
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1617) and 98 other countries.
  • Host Species for Licensed Use: Human
  • Antigen: Inactivated split-virion trivalent vaccine consisting of the FDA-recommended strains of influenza A and influenza B viruses for the 2007/2008 flu season.
  • Preparation: FLUARIX is a sterile suspension prepared from influenza viruses propagated in embryonated chicken eggs. Each influenza viruses is produced and purified separately. After harvesting, each influenza virus is concentrated and purified by zonal centrifugation using a linear sucrose density gradient solution containing detergent to disrupt the viruses. Following dilution, the vaccine is further purified by diafiltration. Each influenza virus solution is inactivated by the consecutive effects of sodium deoxycholate and formaldehyde leading to the production of a “split virus.” Each split inactivated virus is then suspended in sodium phosphate-buffered isotonic sodium chloride solution (GSK: US Fluarix).
  • Immunization Route: Intramuscular injection (i.m.)
  • Virulence: Most adverse events in clinical trials were mild and self-limited.
  • Storage: The prefilled syringe should be shaken well before administration. Do not inject intravenously. Store FLUARIX between 2º and 8ºC (GSK: US Fluarix)
  • Approved Age for Licensed Use: Ages 3 and older (FDA: Fluarix).
  • Contraindication: FLUARIX should not be administered to anyone with known systemic hypersensitivity reactions to egg proteins (eggs or egg products), to chicken proteins, or to any component of FLUARIX or who has had a life-threatening reaction to previous administration of any influenza vaccine (GSK: US Fluarix).
  • Vaccine Ontology ID: VO_0004568
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • M2 from Influenza A virus (A/Puerto Rico/8/34(H1N1)) gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Vector: VR1012 priming, replication-incompetent adenovirus boost (Tompkins et al., 2007)
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response

Human Response

  • Vaccination Protocol: A randomized, double-blind, placebo-controlled study was conducted in healthy subjects 18 to 64 years of age in the United States. After administration of FLUARIX (n = 745), the immune responses to each of the antigens contained in FLUARIX were evaluated in sera obtained 21 days and were compared to those following administration of a placebo vaccine (n = 190).
  • Immune Response: FLUARIX induced strong antibody response with significant hemagglutination inhibition.
  • Immune Response Assay Type: HI antibody assay
  • Side Effects: Adverse effects include varied levels of pain in the injection site, redness, swelling, muscle aches, fatigue, and headache. Immediate, presumably allergic, reactions (e.g., hives, angioedema, allergic asthma, and systemic anaphylaxis) rarely occur after influenza vaccination (GSK: US Fluarix).

Human Response

  • Vaccination Protocol: A randomized, single-blind, active-controlled US study, immunological non-inferiority of FLUARIX (N = 923) was compared with FLUZONE (N = 922), a US-licensed trivalent, inactivated influenza virus vaccine (Sanofi Pasteur SA). Subjects 18 to 64 years and ≥65 years of age were evaluated for immune responses to each of the vaccine antigens 21 days following vaccination (FDA: Fluarix).
  • Immune Response: FLUARIX was non-inferior to the comparator influenza vaccine based on antibody geometric mean titers (GMTs) of serum HI antibodies and the percentage of subjects who achieved seroconversion, defined as at least a 4-fold increase in serum HI titer over baseline to ≥1:40, following vaccination (FDA: Fluarix).
  • Immune Response Assay Type: HI antibody assay

Human Response

  • Vaccination Protocol: The immune response of FLUARIX was compared to FLUZONE, a US-licensed trivalent, inactivated influenza virus vaccine (Sanofi Pasteur SA), in a single-blind, randomized study in a subset of children 6 months to <5 years of age (FDA: Fluarix).
  • Immune Response: Non-inferiority of the immune response for FLUARIX to comparator influenza vaccine for subjects 6 months to <5 years of age was not demonstrated mainly due to lower antibody response to FLUARIX compared to the comparator influenza vaccine in subjects 6 months to <3 years of age. In subjects 3 years to <5 years of age, FLUARIX met at least one of the pre-specified criteria for demonstration of non-inferiority (GMT and seroconversion rate) for the influenza A strains but not for the influenza B strain (FDA: Fluarix).

Human Response

  • Vaccination Protocol: Fluarix was used to vaccinate young healthy human subjects at the age of 18-50 years old. Blood samples were collected from the vaccinees on days 0, 3, and 7 after vaccination. Influenza hemagglutination inhibition assay (HAI) was performed. The peripheral blood mononuclear cells (PBMCs) were isolated. Different cell populations were isolated by flow cytometer. Microarray experiment was then performed using the PBMC samples (Nakaya et al., 2011).
  • Vaccine Immune Response Type: VO_0000286
  • Host ACADM response
    • Description: Compared to Day 0, ACADM was UP regulated in PMBCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host AKR1C3 response
    • Description: Compared to Day 0, AKR1C3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ATF6B response
    • Description: The expression of ATF6B, which is associated with the unfolded protein response, at Day 3 and 7 after vaccination with Fluarix was positively correlated with the baseline-normalized HAI antibody response at day 28 post-vaccination (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CAV1 response
    • Description: Compared to Day 0, CAV1 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD38 response
    • Description: Compared to Day 0, CD38, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HSP90B1 response
    • Description: The expression of HSP90B1, which is associated with the unfolded protein response, at Day 3 and 7 after vaccination with Fluarix was positively correlated with the baseline-normalized HAI antibody response at day 28 post-vaccination (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HYOU1 response
    • Description: Compared to Day 0, HYOU1 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IFNGR2 response
    • Description: Compared to Day 0, IFNGR2 was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGHA1 response
    • Description: Compared to Day 0, IGHA1, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGHM response
    • Description: Compared to Day 0, IGHM, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGKC response
    • Description: Compared to Day 0, IGKC, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGL@ response
    • Description: Compared to Day 0, IGL@, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL10RB response
    • Description: Compared to Day 0, IL10RB was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KDELR2 response
    • Description: Compared to Day 0, KDELR2 was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MANF response
    • Description: The expression of MANF, which is associated with the unfolded protein response, at Day 3 and 7 after vaccination with Fluarix was positively correlated with the baseline-normalized HAI antibody response at day 28 post-vaccination (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MOGS response
    • Description: Compared to Day 0, MOGS was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PDIA4 from humans response
    • Description: he expression of PDIA4, which is associated with the unfolded protein response, at Day 3 and 7 after vaccination with Fluarix was positively correlated with the baseline-normalized HAI antibody response at day 28 post-vaccination (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PDIA6 response
    • Description: Compared to Day 0, PDIA6 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PDIA6 response
    • Description: Compared to Day 0, PDIA6 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PECAM1 response
    • Description: The expression of PECAM1, which is associated with ASC (adipose stromal) cell differentiation, at Day 3 and 7 after vaccination with Fluarix was positively correlated with the baseline-normalized HAI antibody response at day 28 post-vaccination (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host POU2AF1 response
    • Description: The expression of POU2AF1, which is associated with the unfolded protein response, at Day 3 and 7 after vaccination with Fluarix was positively correlated with the baseline-normalized HAI antibody response at day 28 post-vaccination (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host POU2F2 response
    • Description: Compared to Day 0, POU2F2, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RPN1 response
    • Description: Compared to Day 0, RPN1 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RPN2 response
    • Description: Compared to Day 0, RPN2 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEC11C response
    • Description: Compared to Day 0, SEC 11C was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEC23B from humans response
    • Description: Compared to Day 0, SEC 23B was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEC24D response
    • Description: Compared to Day 0, SEC 24D was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SPCS2 response
    • Description: Compared to Day 0, SPCS2 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SRPR response
    • Description: Compared to Day 0, SRPR was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SSR1 response
    • Description: Compared to Day 0, SSR1 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TCF7L2 response
    • Description: Compared to Day 0, TCFL7L2 was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR5 from humans response
    • Description: Compared to Day 0, TLR5 was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFRSF17 response
    • Description: Compared to Day 0, TNFRSF17, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFSF13 response
    • Description: Compared to Day 0, TNFSF13, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TXNDC5 response
    • Description: Compared to Day 0, TXNDC5 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.

Human Response

  • Vaccination Protocol: Fluarix was used to vaccinate young healthy human subjects at the age of 18-50 years old. Blood samples were collected from the vaccinees on days 0, 3, and 7 after vaccination. Influenza hemagglutination inhibition assay (HAI) was performed. The peripheral blood mononuclear cells (PBMCs) were isolated. Different cell populations were isolated by flow cytometer. Microarray experiment was then performed using the PBMC samples (Nakaya et al., 2011). The following host responses are UP regulated gene expressions which experienced at least .33 fold increase in expression.
  • Host AKR1C3 response
    • Description: Compared to Day 0, AKR1C3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011)
    • Detailed Gene Information: Click Here.
  • Host APOBEC3B response
    • Description: Compared to Day 0, [APOBEC3B] was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011)
    • Detailed Gene Information: Click Here.
  • Host APOBEC3F response
    • Description: Compared to Day 0, APOBEC3F was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011)
    • Detailed Gene Information: Click Here.
  • Host ARF1 response
    • Description: Compared to Day 0, ARF1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011)
    • Detailed Gene Information: Click Here.
  • Host ARFIP1 response
    • Description: Compared to Day 0, ARF1P1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011)
    • Detailed Gene Information: Click Here.
  • Host C14orf119 response
    • Description: Compared to Day 0, C14orf119 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host C19orf10 response
    • Description: Compared to Day 0, C19orf10 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host C3AR1 response
    • Description: Compared to Day 0, C3AR1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CASP1 response
    • Description: Compared to Day 0, CASP1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCDC56 response
    • Description: Compared to Day 0, CCDC56 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCR2 response
    • Description: Compared to Day 0, CCR2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD27 response
    • Description: Compared to Day 0, CD27 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD300A response
    • Description: Compared to Day 0, CD300A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD38 response
    • Description: Compared to Day 0, CD38 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CDKN1C response
    • Description: Compared to Day 0, CDKN1C was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host COPB2 response
    • Description: Compared to Day 0, COPB2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CTBP2 response
    • Description: Compared to Day 0, CTBP2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CTSC response
    • Description: Compared to Day 0, CTSC was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CX3CR1 response
    • Description: Compared to Day 0, CX3CR1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CYAT1 response
    • Description: Compared to Day 0, CYAT1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host EAF2 response
    • Description: Compared to Day 0, EAF2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ECHDC1 response
    • Description: Compared to Day 0, ECHDC1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ERLEC1 response
    • Description: Compared to Day 0, [ERLEC1] was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FAM26F response
    • Description: Compared to Day 0, FAM26F was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FKBP11 response
    • Description: Compared to Day 0, FKBP11 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GAPT response
    • Description: Compared to Day 0, GAPT was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GGH response
    • Description: Compared to Day 0, GGH was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GIMAP4 response
    • Description: Compared to Day 0, GIMAP4 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GIMAP8 response
    • Description: Compared to Day 0, GIMAP8 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GPBAR1 response
    • Description: Compared to Day 0, GPBAR1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GTF2H1 response
    • Description: Compared to Day 0, GTF2H1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HSP90B1 response
    • Description: Compared to Day 0, HSP90B1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IDH1 response
    • Description: Compared to Day 0, IDH1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGHD response
    • Description: Compared to Day 0, IGHD was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGHG1 response
    • Description: Compared to Day 0, IGHG1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGHM response
    • Description: Compared to Day 0, IGHM was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGJ response
    • Description: Compared to Day 0, IGJ was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGKC response
    • Description: Compared to Day 0, IGKC was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGKV3-20 response
    • Description: Compared to Day 0, IGKV3-20 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGLL1 response
    • Description: Compared to Day 0, IGLL1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGLV1-44 response
    • Description: Compared to Day 0, IGLV1-44 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGLV2-23 response
    • Description: Compared to Day 0, IGLV2-23 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGLV3-19 response
    • Description: Compared to Day 0, IGLV3-19 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ITM2C response
    • Description: Compared to Day 0, ITM2C was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KCNE3 response
    • Description: Compared to Day 0, KCNE3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KLHL14 response
    • Description: Compared to Day 0, KLHL14 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KLRD1 response
    • Description: Compared to Day 0, KLRD1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LAIR1 response
    • Description: Compared to Day 0, LAIR1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LFNG response
    • Description: Compared to Day 0, LFNG was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC100130100 response
    • Description: Compared to Day 0, LOC100130100 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC100287723 response
    • Description: Compared to Day 0, LOC100287723 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC284837 response
    • Description: Compared to Day 0, LOC284837 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC91316 response
    • Description: Compared to Day 0, LOC91316 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC96610 response
    • Description: Compared to Day 0, LOC96610 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LYST response
    • Description: Compared to Day 0, LYST was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MAN1A1 response
    • Description: Compared to Day 0, MAN1A1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MANF response
    • Description: Compared to Day 0, MANF was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MGAT2 response
    • Description: Compared to Day 0, MGAT2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MOSPD2 response
    • Description: Compared to Day 0, MOSPD2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MS4A4A response
    • Description: Compared to Day 0, MS4A4A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MS4A7 response
    • Description: Compared to Day 0, MS4A7 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NDUFA8 response
    • Description: Compared to Day 0, NDUFA8 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host OSTM1 response
    • Description: Compared to Day 0, OSTM1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PCMT1 response
    • Description: Compared to Day 0, PCMT1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PDIA5 response
    • Description: Compared to Day 0, PDIA5 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PMS2P2 response
    • Description: Compared to Day 0, PMS2P2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host POU2AF1 response
    • Description: Compared to Day 0, POU2AF1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PPAPDC1B response
    • Description: Compared to Day 0, PPAPDC1B was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PRDX4 response
    • Description: Compared to Day 0, PRDX4 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PRF1 response
    • Description: Compared to Day 0, PRF1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RAB10 response
    • Description: Compared to Day 0, RAB10 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RAB8A response
    • Description: Compared to Day 0, RAB8A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RAP2A response
    • Description: Compared to Day 0, RAP2A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RNASE2 response
    • Description: Compared to Day 0, RNASE2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RPS27 response
    • Description: Compared to Day 0, RPS27 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RRM2 response
    • Description: Compared to Day 0, RRM2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEC11C response
    • Description: Compared to Day 0, SEC 11C was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEC24A response
    • Description: Compared to Day 0, SEC 24A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEC61A1 response
    • Description: Compared to Day 0, SEC1A1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEL1L3 response
    • Description: Compared to Day 0, SEL1L3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SH2D1B response
    • Description: Compared to Day 0, SH2D1B was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SLAMF6 response
    • Description: Compared to Day 0, SLAMF6 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SLAMF7 response
    • Description: Compared to Day 0, SLAMF7 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SLC44A1 response
    • Description: Compared to Day 0, SLC44A1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SNORA28 response
    • Description: Compared to Day 0, SNORA28 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SPTLC2 response
    • Description: Compared to Day 0, SPTLC2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SSR3 response
    • Description: Compared to Day 0, SSR3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host STT3A response
    • Description: Compared to Day 0, STT3A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SUV420H1 response
    • Description: Compared to Day 0, SUV420H1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR5 from humans response
    • Description: Compared to Day 0, TLR5 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR8 response
    • Description: Compared to Day 0, TLR8 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFAIP8L2 response
    • Description: Compared to Day 0, TNFAIP8L2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFRSF17 response
    • Description: Compared to Day 0, TNFRSF17 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNIP1 response
    • Description: Compared to Day 0, TNIP1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TPD52 response
    • Description: Compared to Day 0, TPD52 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TRAM2 response
    • Description: Compared to Day 0, TRAM2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TRIM69 response
    • Description: Compared to Day 0, TRIM69 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TXNDC5 response
    • Description: Compared to Day 0, TXNDC5 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TYMS response
    • Description: Compared to Day 0, TYMS was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host VPS35 response
    • Description: Compared to Day 0, VPS35 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZEB2 response
    • Description: Compared to Day 0, ZEB2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZKSCAN1 response
    • Description: Compared to Day 0, ZKSCAN1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZNF146 response
    • Description: Compared to Day 0, ZNF146 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZNF207 response
    • Description: Compared to Day 0, ZNF207 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZNF573 response
    • Description: Compared to Day 0, ZNF573 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZWINT response
    • Description: Compared to Day 0, ZWINT was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.

Baboon Response

  • Vaccination Protocol: Fluarix was used to vaccinate young healthy human subjects at the age of 18-50 years old. Blood samples were collected from the vaccinees on days 0, 3, and 7 after vaccination. Influenza hemagglutination inhibition assay (HAI) was performed. The peripheral blood mononuclear cells (PBMCs) were isolated. Different cell populations were isolated by flow cytometer. Microarray experiment was then performed using the PBMC samples (Nakaya et al., 2011).
  • Vaccine Immune Response Type: VO_0000286

Baboon Response

  • Vaccination Protocol: DNA vaccination at doses of 50 μg/mouse in low-endotoxin PBS was given intramuscularly in the quadriceps, half to each leg, in 3 doses 2 weeks apart. In some experiments, mice were given a booster injection of rAd intramuscularly at a dose of 1010 particles/mouse, 2–3 weeks after the last dose of DNA (Tompkins et al., 2007).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Mice primed with M2-DNA and then boosted with recombinant adenovirus expressing M2 (M2-Ad) had enhanced antibody responses that cross-reacted with human and avian M2 sequences and induced T-cell responses (Tompkins et al., 2007).
  • Challenge Protocol: Challenge virus in 50 μL of PBS was administered intranasally to anesthetized mice. Isoflurane or ketamine/xylazine was used for mice challenged with H1N1 subtype. Subtype H5N1 was administered intranasally to mice anesthetized with 2,2,2-tribromoethanol in tert-amyl alcohol (Tompkins et al., 2007).
  • Efficacy: Of mice vaccinated with M2-DNA, 100% survived challenge with A/PR/8 and A/FM virus, both subtypes of the H1N1 virus (Tompkins et al., 2007).
References References
FDA: Fluarix: FDA: Fluarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112850.htm]
GSK: US Fluarix: GSK: US Fluarix vaccine information [http://us.gsk.com/products/assets/us_fluarix.pdf]
Nakaya et al., 2011: Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, Means AR, Kasturi SP, Khan N, Li GM, McCausland M, Kanchan V, Kokko KE, Li S, Elbein R, Mehta AK, Aderem A, Subbarao K, Ahmed R, Pulendran B. Systems biology of vaccination for seasonal influenza in humans. Nature immunology. 2011; 12(8); 786-795. [PubMed: 21743478].
Tompkins et al., 2007: Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging infectious diseases. 2007; 13(3); 426-435. [PubMed: 17552096].